MIRM Q3 2021 Earnings — Mirum Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

MIRMMirum Pharmaceuticals, Inc.

$5B

Q3 2021 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$5M

Gross Profit

$5M100.0% margin

Operating Income

-$43M-856.5% margin

Net Income

-$47M-942.2% margin

EPS (Diluted)

$-1.55

QoQ Revenue Growth

-54.5%

Cash Flow

Operating Cash Flow

-$34M

Free Cash Flow

-$34M

Stock-Based Comp.

$7M

Balance Sheet

Total Assets

$235M

Total Liabilities

$179M

Stockholders' Equity

$56M

Cash & Equivalents

$56M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$5M	$0	—
Gross Profit	$5M	$0	—
Operating Income	-$43M	-$22M	-97.2%
Net Income	-$47M	-$22M	-119.0%